These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The effect of recombinant human tumor necrosis factor-alpha on Ehrlich ascites tumor growth.
    Author: Terlikowski S, Sulkowska M, Nowak HF.
    Journal: J Environ Pathol Toxicol Oncol; 2002; 21(1):87-92. PubMed ID: 11934018.
    Abstract:
    We studied the antitumor effect of recombinant human tumor necrosis factor-alpha (rhTNF-alpha) on the intraperitoneal (i.p.) growth of Ehrlich ascites tumor (EAT) in Swiss albino male mice. The animals were treated with i.p. injection of rhTNF-alpha in doses of 5, 7.5, or 10 microg three times a week for 2 weeks, respectively, starting on the 4th day after the EAT inoculation. The effect of the cytokine was evaluated based on the following parameters: total ascites volume, packed cell volume, total packed cell volume, inhibitory growth rate, cellular population of EAT, morphological EAT cell changes, and mean survival time (MST). RhTNF-alpha in a dose of 5 microg had only a slight effect on MST and inhibitory growth rate (IGR). After a dose of 7.5 microg, an increased IGR (p < 0.01) was observed, but the animals did not live longer than the controls. After 7.5- and 10-microg doses (p < 0.001), the number of cells in EAT decreased significantly and enhanced cellular damage to EAT cells was found. In mice treated with 10 microg, a significant IGR (p < 0.001) was accompanied by enhancement of MST (p < 0.01). Although the 10 microg dose exerted a greater effect compared with the remaining doses, no complete regression was attained.
    [Abstract] [Full Text] [Related] [New Search]